Home › Funds › ARCH Venture Management, LLC › RAPP
ARCH Venture Management, LLC position in RAPP
RAPPORT THERAPEUTICS INC · Health Care
ARCH Venture Management, LLC reported holding 3,728,738 shares of RAPP (RAPPORT THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$155.4M, representing 14.12% of its reported portfolio and ranking #3 among its reported holdings. ARCH Venture Management, LLC has disclosed RAPP holdings in 9 of the last 9 reported quarters, going back to Q2 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How ARCH Venture Management, LLC's RAPP position evolved
ARCH Venture Management, LLC first disclosed a stake in RAPP in Q2 2024 at 3,728,738 shares (US$86.7M). The position peaked in Q2 2026 at 3,728,738 shares, worth US$155.4M. Across 9 filings, ARCH Venture Management, LLC held the position steady without any share-count change. The most recent filing (Q2 2026) shows 3,728,738 shares valued at US$155.4M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2024 | 3.73M | $86.73M | New |
| Q3 2024 | 3.73M | $76.36M | Hold |
| Q4 2024 | 3.73M | $66.15M | Hold |
| Q1 2025 | 3.73M | $37.55M | Hold |
| Q2 2025 | 3.73M | $42.43M | Hold |
| Q3 2025 | 3.73M | $110.74M | Hold |
| Q4 2025 | 3.73M | $113.13M | Hold |
| Q1 2026 | 3.73M | $116.67M | Hold |
| Q2 2026 | 3.73M | $155.38M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About RAPP and 13F data
RAPP (RAPPORT THERAPEUTICS INC) is a Health Care company. 66 other funds we track also report a position in RAPP — the largest reported positions include TRV GP V, LLC (US$261.7M), Cormorant Asset Management, LP (US$110.7M), Sofinnova Investments, Inc. (US$79.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RAPP
- TRV GP V, LLC 6.28M sh · $261.71M · Q2 2026
- Cormorant Asset Management, LP 2.66M sh · $110.74M · Q2 2026
- Sofinnova Investments, Inc. 1.90M sh · $79.36M · Q2 2026
- JOHNSON & JOHNSON 1.78M sh · $74.36M · Q2 2026
- BAKER BROS. ADVISORS LP 1.55M sh · $64.47M · Q2 2026
- TRV GP VI, LLC 969.22K sh · $40.39M · Q2 2026
- PERCEPTIVE ADVISORS LLC 773.34K sh · $32.23M · Q2 2026
- Vestal Point Capital, LP 730.00K sh · $30.42M · Q2 2026
- Siren, L.L.C. 641.47K sh · $26.73M · Q2 2026
- Sio Capital Management, LLC 307.66K sh · $12.82M · Q2 2026
- Burkehill Global Management, LP 250.00K sh · $10.42M · Q2 2026
- Artia Global Partners LP 138.51K sh · $5.77M · Q2 2026
More on ARCH Venture Management, LLC
FAQ
How long has ARCH Venture Management, LLC held RAPP?
ARCH Venture Management, LLC has disclosed RAPP holdings in 9 of the last 9 reported quarters, going back to Q2 2024.
What is ARCH Venture Management, LLC's current position in RAPP?
As of Q2 2026, ARCH Venture Management, LLC holds 3.73M shares of RAPP (RAPPORT THERAPEUTICS INC), valued at $155.38M, representing 14.12% of its reported portfolio and ranking #3.
Has ARCH Venture Management, LLC been buying or selling RAPP?
In the latest 13F filing (Q2 2026), ARCH Venture Management, LLC held unchanged its position in RAPP. The position peaked in Q2 2026 at 3.73M shares.
Which other funds hold RAPP?
Other major institutional holders of RAPP include TRV GP V, LLC, Cormorant Asset Management, LP, Sofinnova Investments, Inc., among 66 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.